Vanda Pharmaceuticals (VNDA) Gains FDA Approval to Proceed with IND for VSJ-110 for Allergic Conjunctivitis

Go back to Vanda Pharmaceuticals (VNDA) Gains FDA Approval to Proceed with IND for VSJ-110 for Allergic Conjunctivitis
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Delayed: 5.23 -0.1 (1.88%)
Previous Close $5.33    52 Week High $18.00 
Open $5.29    52 Week Low $6.91 
Day High $5.35    P/E N/A 
Day Low $5.22    EPS $-0.67 
Volume 258,708